Περίληψη:
The introduction of immune checkpoint inhibitors (ICIs) opened a new era
in oncologic therapy. The favourable profile of ICIs in terms of
efficacy and safety can be overshadowed by the development of
immune-related adverse events (irAEs). Dermatologic irAEs (dirAEs)
appear in about 40% of patients undergoing immunotherapy and mainly
include maculopapular, psoriasiform, lichenoid and eczematous rashes,
auto-immune bullous disorders, pigmentary disorders, pruritus, oral
mucosal lesions, hair and nail changes, as well as a few rare and
potentially life-threatening toxicities. The EADV task force Dermatology
for Cancer Patients merged the clinical experience of the so-far
published data, incorporated the quantitative and qualitative
characteristics of each specific dirAEs, and released
dermatology-derived, phenotype-specific treatment recommendations for
cutaneous toxicities (including levels of evidence and grades of
recommendation). The basic principle of management is that the
interventions should be tailored to serve the equilibrium between
patients’ relief from the symptoms and signs of skin toxicity and the
preservation of an unimpeded oncologic treatment.
Συγγραφείς:
Apalla, Z.
Nikolaou, V
Fattore, D.
Fabbrocini, G. and
Freites-Martinez, A.
Sollena, P.
Lacouture, M.
Kraehenbuehl,
L.
Stratigos, A.
Peris, K.
Lazaridou, E.
Richert, B. and
Vigarios, E.
Riganti, J.
Baroudjian, B.
Filoni, A. and
Dodiuk-Gad, R.
Lebbe, C.
Sibaud, V
